Oruka Therapeutics (NASDAQ:ORKA) Releases Earnings Results, Beats Estimates By $0.19 EPS

Oruka Therapeutics (NASDAQ:ORKA) issued its earnings results on Thursday. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.19, Zacks reports.

Oruka Therapeutics Stock Down 3.0 %

Shares of ORKA stock opened at $10.07 on Friday. The company has a market cap of $352.44 million, a P/E ratio of -1.61 and a beta of 0.67. Oruka Therapeutics has a 12-month low of $9.44 and a 12-month high of $31.13. The company’s 50-day moving average price is $13.44.

Insiders Place Their Bets

In other Oruka Therapeutics news, major shareholder Venrock Healthcare Capital Par bought 8,971 shares of the firm’s stock in a transaction dated Wednesday, February 12th. The shares were bought at an average price of $11.86 per share, for a total transaction of $106,396.06. Following the completion of the acquisition, the insider now owns 4,044,684 shares of the company’s stock, valued at approximately $47,969,952.24. This trade represents a 0.22 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have bought 98,339 shares of company stock valued at $1,128,456. 22.67% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ORKA. HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wolfe Research initiated coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 price target for the company. Finally, Wedbush restated an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $39.86.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.